Travere Therapeutics Inc Forecast, price target & analysts
Travere Therapeutics Inc Target price 2025 - Analyst rating & recommendation
Travere Therapeutics Inc Classifications & Recommendation:
Travere Therapeutics Inc Price Target
| Target Price | $35.70 |
| Price | $24.64 |
| Potential |
44.89%
register free of charge
|
| Number of Estimates | 16 |
|
16 Analysts have issued a price target Travere Therapeutics Inc 2026 .
The average Travere Therapeutics Inc target price is $35.70.
This is
44.89%
register free of charge
$49.35
100.28%
register free of charge
$25.25
2.48%
register free of charge
|
|
| A rating was issued by 21 analysts: 18 Analysts recommend Travere Therapeutics Inc to buy, 3 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Travere Therapeutics Inc stock has an average upside potential 2026 of
44.89%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 233.18 | 428.75 |
| 60.55% | 83.87% | |
| EBITDA Margin | -91.97% | -15.39% |
| 60.77% | 83.27% | |
| Net Margin | -137.90% | -24.74% |
| 79.79% | 82.06% |
16 Analysts have issued a sales forecast Travere Therapeutics Inc 2025 . The average Travere Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
7 Analysts have issued an Travere Therapeutics Inc EBITDA forecast 2025. The average Travere Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
16 Travere Therapeutics Inc Analysts have issued a net profit forecast 2025. The average Travere Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -4.06 | -1.19 |
| 172.48% | 70.69% | |
| P/E | negative | |
| EV/Sales | 5.26 |
16 Analysts have issued a Travere Therapeutics Inc forecast for earnings per share. The average Travere Therapeutics Inc EPS is
This results in the following potential growth metrics and future valuations:
Travere Therapeutics Inc...
Current Travere Therapeutics Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Sep 19 2025 |
| Stifel |
Locked
➜
Locked
|
Locked | Sep 12 2025 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Sep 11 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Sep 10 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Sep 03 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 28 2025 |
| Wedbush |
Locked
➜
Locked
|
Locked | Aug 07 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Sep 19 2025 |
|
Locked
Stifel:
Locked
➜
Locked
|
Sep 12 2025 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Sep 11 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Sep 10 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Sep 03 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 28 2025 |
|
Locked
Wedbush:
Locked
➜
Locked
|
Aug 07 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
